
Martin Zapata Laguado/LinkedIn
Jun 2, 2025, 06:19
Martin Zapata Laguado: KN564 maintain benefit on OS in ccRCC
Martin Zapata Laguado, Clinical Oncologist at the National Cancer Institute E.S.E., shared on X:
“ASCO 2025 update data on KN564 maintain benefit on OS, all patients in the trial benefit from Pembrolizumab adjuvant, however we lack more biomarkers perhaps a measure in KIM1 would be outstanding.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 25, 2025, 22:02
Jul 25, 2025, 21:34
Jul 25, 2025, 21:01
Jul 25, 2025, 20:41
Jul 25, 2025, 20:07
Jul 25, 2025, 19:11
Jul 25, 2025, 17:20
Jul 25, 2025, 16:55